Aimmune Therapeutics (AIMT) Misses Q4 EPS by 4c

Aimmune Therapeutics (NASDAQ: AIMT) reported Q4 EPS of ($0.39), $0.04 worse than the analyst estimate of ($0.35).

For earnings history and earnings-related data on Aimmune Therapeutics (AIMT) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
• Is the global equity rally broadening? UBS weighs in